Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors; Cancers; Vol. 15 - iss. 6
| Parent link: | Cancers.— .— Basel: MDPI AG Vol. 15 - iss. 6.— 2023.— Article number 1631, P. 1-15 |
|---|---|
| Autor kompanije: | |
| Daljnji autori: | , , , , , , , , , , , , , , |
| Sažetak: | The gastrin-releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PCa) and in hormone-driven breast cancer (BCa). The aim of this phase I clinical trial was to evaluate safety, biodistribution, and dosimetry after the administration of the recently developed GRPR-targeting antagonistic bombesin analogue [99mTc]Tc-maSSS-PEG2-RM26 in PCa and BCa patients. Planar and whole-body SPECT/CT imaging was performed in six PCa patients and seven BCa patients 2, 4, 6, and 24 h post the intravenous administration of 40 µg of [99mTc]Tc-maSSS-PEG2-RM26 (600–700 MBq). No adverse events or pathological changes were observed. The rapid blood clearance of [99mTc]Tc-maSSSPEG2-RM26 was observed with predominantly hepatobiliary excretion. The effective doses were 0.0053 ± 0.0007 for male patients and 0.008 ± 0.003 mSv/MBq for female patients. The accumulation of [99mTc]Tc-maSSS-PEG2-RM26 in tumors was observed in four out of six PCa and in seven out of seven BCa patients. In four BCa patients, a high uptake of the agent into the axillary lymph nodes was detected. Immunohistochemistry revealed positive GRPR expression in 60% of primary PCa, 71.4% of BCa tumors, and 50% of examined BCa lymph nodes. In conclusion, a single administration of [99mTc]Tc-maSSS-PEG2-RM26 was safe and well tolerated. [99mTc]Tc-maSSS-PEG2-RM26 SPECT may be useful for tumor detection in PCa and BCa patients, pending further studies.
Текстовый файл |
| Jezik: | engleski |
| Izdano: |
2023
|
| Teme: | |
| Online pristup: | https://doi.org/10.3390/cancers15061631 |
| Format: | Elektronički Poglavlje knjige |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=671233 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 671233 | ||
| 005 | 20251204155319.0 | ||
| 014 | |2 sici | ||
| 090 | |a 671233 | ||
| 100 | |a 20240305d2023 k||y0rusy50 ca | ||
| 101 | 1 | |a eng |c rus | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a a |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors |f V. Chernov, A. Rybina, R. Zelchan [et all.] |d Фаза I исследования [99mTc] Tc-maSSS-PEG2-RM26, аналога бомбезина, антагониста рецепторов гастрин-рилизинг-пептидов (GRPRs), для ОФЭКТ-визуализации экспрессии GRPR в злокачественных опухолях |z rus | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 320 | |a References : p. 13-15 (43 tit.) | ||
| 330 | |a The gastrin-releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PCa) and in hormone-driven breast cancer (BCa). The aim of this phase I clinical trial was to evaluate safety, biodistribution, and dosimetry after the administration of the recently developed GRPR-targeting antagonistic bombesin analogue [99mTc]Tc-maSSS-PEG2-RM26 in PCa and BCa patients. Planar and whole-body SPECT/CT imaging was performed in six PCa patients and seven BCa patients 2, 4, 6, and 24 h post the intravenous administration of 40 µg of [99mTc]Tc-maSSS-PEG2-RM26 (600–700 MBq). No adverse events or pathological changes were observed. The rapid blood clearance of [99mTc]Tc-maSSSPEG2-RM26 was observed with predominantly hepatobiliary excretion. The effective doses were 0.0053 ± 0.0007 for male patients and 0.008 ± 0.003 mSv/MBq for female patients. The accumulation of [99mTc]Tc-maSSS-PEG2-RM26 in tumors was observed in four out of six PCa and in seven out of seven BCa patients. In four BCa patients, a high uptake of the agent into the axillary lymph nodes was detected. Immunohistochemistry revealed positive GRPR expression in 60% of primary PCa, 71.4% of BCa tumors, and 50% of examined BCa lymph nodes. In conclusion, a single administration of [99mTc]Tc-maSSS-PEG2-RM26 was safe and well tolerated. [99mTc]Tc-maSSS-PEG2-RM26 SPECT may be useful for tumor detection in PCa and BCa patients, pending further studies. | ||
| 336 | |a Текстовый файл | ||
| 461 | 1 | |c Basel |n MDPI AG |t Cancers | |
| 463 | 1 | |d 2023 |t Vol. 15 - iss. 6 |v Article number 1631, P. 1-15 | |
| 610 | 1 | |a GRPR | |
| 610 | 1 | |a antagonist | |
| 610 | 1 | |a 99mTc | |
| 610 | 1 | |a phase I trial | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a электронный ресурс | |
| 701 | 1 | |a Chernov |b V. I. |c specialist in the field of medical technology |c lead engineer of Tomsk Polytechnic University, doctor of medical sciences |f 1962- |g Vladimir Ivanovich |9 17725 | |
| 701 | 1 | |a Rybina |b A. N. |g Anastasiya Nikolaevna |f 1982- |c specialist in the field of biophysics |c Researcher of Tomsk Polytechnic University, Candidateof medical Sciences |y Tomsk |9 88810 | |
| 701 | 1 | |a Zelchan (Zeltchan) |b R. V. |c specialist in the field of medical technology |c Researcher of the Tomsk Polytechnic University, Candidate of Medical Sciences |f 1984- |g Roman Vladimirovich |9 17728 | |
| 701 | 1 | |a Medvedeva |b А. А. |g Anna Aleksandrovna |f 1975- |c specialist in the field of medical technology |c research fellow of Tomsk Polytechnic University, Doctor of Medical Sciences |y Tomsk |9 20294 | |
| 701 | 1 | |a Bragina |b O. D. |c specialist in the field of medical technology |c Senior Researcher of the Tomsk Polytechnic University, Doctor of Medical Sciences |f 1986- |g Olga Dmitrievna |y Tomsk |9 19084 | |
| 701 | 1 | |a Lushnikova |b N. |g Nadejda | |
| 701 | 1 | |a Doroshenko |b A. |g Artem | |
| 701 | 1 | |a Usynin |b E. |g Evgeniy | |
| 701 | 1 | |a Tashireva |b L. |g Liubov | |
| 701 | 1 | |a Vtorushin |b S. |g Sergey | |
| 701 | 1 | |a Abouzayed |b A. |g Ayman | |
| 701 | 1 | |a Rinne |b S. S. |g Sara | |
| 701 | 1 | |a Sorensen |b J. |g Jens | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 701 | 1 | |a Orlova |b A. M. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1960- |g Anna Markovna |9 22212 | |
| 712 | 0 | 2 | |a National Research Tomsk Polytechnic University |c (2009- ) |9 27197 |
| 801 | 0 | |a RU |b 63413507 |c 20240305 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.3390/cancers15061631 |z https://doi.org/10.3390/cancers15061631 | |
| 942 | |c CR | ||